Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J And Novartis (Part 3)
This article was originally published in PharmAsia News
In Part 3 of our feature, we take a closer look at the first quarterly calls for Abbott and AbbVie after the company split in two, plus the latest on emerging markets from J&J and Novartis.
You may also be interested in...
AbbVie Sets Out To Win Over Investors In Its First Financial Call
Management highlighted the ongoing growth potential of Humira and a late-stage pipeline that it says has the ability to generate between $4 billion and $6 billion of growth during the new pharmaceutical company’s first financial call with investors.
J&J Considers Sale, Spin-Off For Ortho-Clinical Diagnostics
Johnson & Johnson announced plans to evaluate strategic options for its Ortho-Clinical Diagnostics unit during the firm’s medical devices and diagnostics business review.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.